The role of interferon-alpha in the immunological response against the background of antiviral therapy for chronic hepatitis C in patients with HCV/HIV co-infection

Written by Lee Y.A., Sklyar L.F., Markelova E.V., Borisenko E.A.

  UDK: 616.36–002.2–06:616.98:578.828HIV–085.281/.37 | Pages: 52–54 | Full text PDF | Open PDF 

Background. Analyzed interrelations of clinical and laboratory effects of interferon-alpha (IFNα) and the content of T-helper cells in patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) at the background of antiviral treatment of chronic hepatitis C.
Methods. Observed 289 people (182 men and 107 women) aged 35,0±4,7 years co-infected with HCV/HIV receiving pegylated IFNα-2a and ribavirin for 48 weeks.
Results. Sustained virological response (without the presence of HCV genome in serum) was registered in 172 cases, and the effectiveness of treatment of chronic hepatitis C among all patients was at the level of 59.5 %. On the background of antiviral treatment for hepatitis up to the 12th week of the number of CD4+ T cells was significantly reduced in all patients regardless of the presence or absence of antiretroviral therapy.
Conclusions. A significant increase in the level of IFNα in blood of patients with the administration of pegylated IFNα-2a implements mechanisms of its negative impact on the course of HIV infection, causing fluctuations in levels of CD4+ lymphocytes.

Links to authors:

Y.A. Lee, L.F. Sklyar, E.V. Markelova, E.A. Borisenko
Pacific State Medical University (2 Ostryakova Ave. Vladivostok 690950 Russian Federation)

1. Ershov F.I., Narovlyanskiy A.N. The main results of the study of interferon system by 2011 // Interferon-2011: collected works. М., 2012. P. 14–34.
2. Karaulov A.V., Kalyuzhin O.V. Immunotherapy of infectious diseases: problems and prospects // Therapeutic Archive. 2013. No. 11. P. 100–108.
3. Kravchenko A.V., Gankina N.Yu., Kanestri V.G. [et al.]. Clinical supervision , treatment and prevention of viral hepatitis in adolescents and adult patients with HIV infection: methodical recommendations. М., 2007. 20 p.
4. Kravchenko A.V., Gankina N.Yu., Kanestri V.G. Features of an antiretroviral therapy with a combination of HIV infection and chronic hepatitis B // Farmateka. 2008. Vol. 19. P. 1–8.
5. Recommendations for the diagnosis and treatment of adult patients with hepatitis C. М.: MOH RF, 2013. 86 p.
6. Sklyar L.F., Li Yu.A., Gorelova I.S. Antiviral therapy of parenteral hepatitis in HIV-infected patients in the Primorskiy Territory // Pacific Medical Journal. 2009. No 4. P. 82–85.
7. Sklyar L.F., Zima L.G., Li Yu.A. [et al.]. The efficacy of treatment with pegylated interferon alpha and ribavirin, 2 co-infection HIV/ HCV // Pacific Medical Journal. 2010. No. 4. P. 81–84.
8. TsaregorotsevaT.M., Serova T.I. Cytokines in gastroenterology. М.: Anakharsis, 2003. 95 p.
9. European AIDS Clinical Society (EACS) Guidelines, Version 7.0. 2013. Part IV. 298 р.
10. Herbeuval J.P., Shearer G.M. HIV-1 immunopathogenesis: how good interferon turns bad // Clin. Immunol. 2007. Vol. 123. P. 121–128.
11. Malleret B., Maneglier B., Karlsson I. [et al.] Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I IFN and immune suppression // Blood. 2008. Р. 598-608. [Epub ahead of print]. URL: http://www.ncbi.nlm.nih.gov/pubmed/18787223 (date of access: 17.11.2014).


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.